Regeneron Pharma (REGN) PT Raised to $494 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Regeneron (REGN), Sanofi (SNY) Enter Global Immunooncology Collaboration for Antibody Cancer Treatments
July 28, 2015 7:47 AM EDTRegeneron (NASDAQ: REGN) and Sanofi (NYSE: SNY) have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. As part of the agreement, the two companies will jointly develop a programmed cell death protein 1 (PD-1) inhibitor currently in Phase 1 testing and plan to initiate clinical trials in 2016 with new therapeutic candidates based on ongoing, innovative preclinical programs.
"The field of immuno-oncology has shown the potential to dramatically improve outcomes for patients with certain... More
Regeneron (REGN) Investors Already Pricing-in Praluent Approval; Roth Capital Affirms at 'Neutral'
July 27, 2015 8:57 AM EDTRoth Capital affirms Regeneron Pharmaceuticals (Nasdaq: REGN) with a Neutral rating and $495 price target, saying Praluent approval has already been priced into the stock.
Analyst Joseph Pantginis commented, This approval represents another major achievement for REGN and we believe remains priced into the stock. We believe... More
Regeneron (REGN), Sanofi (SNY) Announce FDA Approval of Praluent
July 24, 2015 3:19 PM EDT(Updated - July 24, 2015 3:20 PM EDT)
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) approved Praluent® (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein (LDL) cholesterol. The effect of Praluent on cardiovascular morbidity and... More
FDA Approves Sanofi (SNY)/Regeneron's (REGN) Praluent to Treat Certain Patients with High Cholesterol
July 24, 2015 2:21 PM EDTThe U.S. Food and Drug Administration today approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.
Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol.
HeFH is an inherited condition that causes high levels of low-density lipoprotein (LDL) cholesterol. A high level of LDL cholesterol (known as bad... More
